MDS 2023 | The use of NGS to better risk stratify patients & identify druggable mutations in MDS
Norbert Vey
• 5 May 2023
Norbert Vey, MD, PhD, Paoli-Calmettes Institute, Marseille, France, discusses the use of next-generation sequencing (NGS) in clinical practice to help better risk stratify patients and identify druggable mutations in myelodysplastic syndromes (MDS). Dr Vey also highlights challenges in access to this technology. This interview took place at the 17th International Congress on Myelodysplastic Syndromes 2023 (MDS 2023) held in Marseille, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
